Oprelvekin Dosing
The recommended dose of oprelvekin (recombinant interleukin-11) for adults is 50 mcg/kg subcutaneously once daily, starting 6-24 hours after chemotherapy completion and continuing until the post-nadir platelet count reaches ≥50,000/μL, not to exceed 21 days of treatment 1.
Adult Dosing
- Standard dose: 50 mcg/kg subcutaneously once daily
- Timing: Begin 6-24 hours after completing chemotherapy
- Duration: Continue until post-nadir platelet count ≥50,000/μL
- Maximum duration: Do not exceed 21 days (not adequately studied beyond this timeframe) 1
Severe Renal Impairment
For patients with severe renal impairment (creatinine clearance <30 mL/min), reduce the dose to 25 mcg/kg subcutaneously once daily 1. This represents a 50% dose reduction from the standard adult dose due to decreased renal clearance and increased risk of fluid retention and cardiovascular complications in this population.
Pediatric Dosing (Children >12 years)
The recommended pediatric dose is 75 mcg/kg subcutaneously once daily, using the same timing and duration parameters as adults 1, 2. This higher weight-based dose in children accounts for differences in pharmacokinetics and drug clearance compared to adults.
Pediatric Considerations:
- Begin 6-24 hours after chemotherapy completion
- Continue until post-nadir platelet count ≥50,000/μL
- Maximum 21 days of treatment
- The 75 mcg/kg dose was established in phase I/II trials showing improved hematological recovery and reduced platelet transfusion requirements 2
Critical Caveats
Fluid retention and cardiovascular effects are dose-limiting toxicities. Monitor closely for:
- Peripheral edema
- Dyspnea
- Tachycardia
- Pleural effusions
- Atrial arrhythmias
These effects are particularly pronounced in elderly patients and those with renal impairment, necessitating the dose reduction outlined above 1, 3.
Do not use in patients with pre-existing papilledema or significant fluid overload, as oprelvekin can exacerbate these conditions 2.